MapLight Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 registration statement on November 16, 2026, converting it into a Form S-3 and updating the prospectus for the resale of up to 13,160,261 shares of common stock by selling stockholders.

Key Highlights

  • Shares covered: Up to 13,160,261 shares of voting common stock are covered by the updated prospectus, consisting of 9,177,093 shares of common stock and 3,983,168 shares issuable upon exercise of outstanding pre-funded warrants.
  • Private Placement origin: All shares were issued in a private placement that closed on August 14, 2026.
  • No new securities registered: According to the filing, no additional securities are being registered under this Post-Effective Amendment.
  • No company proceeds: The company disclosed it will not receive any proceeds from any sale of common stock by the selling stockholders pursuant to this prospectus.
  • Last reported share price: On November 13, 2026, the last reported sale price for the company's common stock on the Nasdaq Global Select Market was $7.25 per share.
  • Original registration: The initial Form S-1 (File No. 333-298837) was filed on September 9, 2026, amended on September 18, 2026, and declared effective on September 23, 2026.

MapLight Therapeutics Converts Resale Registration From S-1 to S-3

MapLight Therapeutics, Inc. (NASDAQ:MPLT), a Delaware-incorporated biopharmaceutical company headquartered in Redwood City, California, filed this Post-Effective Amendment No. 1 to update and convert its earlier Form S-1 registration statement into a Form S-3. According to the filing, the amendment serves four purposes: converting the registration form type, updating the number of securities being offered, updating information regarding the selling stockholders, and updating certain company information.

The prospectus covers the proposed resale or other disposition by identified selling stockholders of up to 13,160,261 shares of voting common stock, par value $0.0001 per share. This total comprises 9,177,093 shares of common stock and 3,983,168 shares of common stock issuable upon the exercise of outstanding pre-funded warrants. The filing notes that the company has two series of common stock, voting and non-voting, and that the registration covers only voting common stock. All shares originated from a private placement that closed on August 14, 2026.

The company disclosed that the registration of the resale does not mean the selling stockholders will offer or sell all or any of the shares. The filing states that shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices determined at the time of sale, or at negotiated prices. The company disclosed it has agreed to bear registration expenses, except for any underwriting discounts and commissions, which will be borne by the selling stockholders. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under applicable SEC definitions.

What Was Disclosed

MapLight Therapeutics filed a Post-Effective Amendment No. 1 converting its resale registration from Form S-1 to Form S-3, covering up to 13,160,261 shares of voting common stock issued in connection with an August 14, 2026 private placement. No new securities were registered and no company proceeds are expected from the resales.